Concepedia

Author

Juliette Janson

AstraZeneca (Sweden)

Also Known As

J JANSON, J Janson, J. Janson, Juliette Janson, Y. Gravenfors

30

Publications

7.3K

Citations

18

H-Index

47

Concepts

All Affiliations

AstraZeneca (Sweden)Karolinska InstitutetUniversity of Southern CaliforniaScience for Life LaboratoryPfizer (United States)
JJ

About

Juliette Janson is an author at AstraZeneca (Sweden) specializing in medicine, pharmacology, and neuroprotection.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

801

2

Biochemistry

3

3

226

3

Health Sciences

2

2

217

4

Natural Sciences

2

2

151

5

Social Sciences

1

1

11

Juliette Janson

×

19

Publications

7.3K

Citations

18

H-Index

YearCitations

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Alexandra E. Butler, Juliette Janson, Susan Bonner‐Weir,

Diabetes

2003

4K

Increased Risk of Type 2 Diabetes in Alzheimer Disease

Juliette Janson, Thomas Laedtke, Joseph E. Parisi,

Diabetes

2004

939

The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles.

Juliette Janson, Richard H. Ashley, David J. Harrison,

Diabetes

1999

609

Increased β-Cell Apoptosis Prevents Adaptive Increase in β-Cell Mass in Mouse Model of Type 2 Diabetes

Alexandra E. Butler, Juliette Janson, Walter C. Soeller,

Diabetes

2003

407

Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide.

Juliette Janson, Walter C. Soeller, Patrick C. Roche,

Proceedings of the National Academy of Sciences

1996

337

Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide.

Walter C. Soeller, Juliette Janson, S E Hart,

Diabetes

1998

142

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

Fredrik Jeppsson, Susanna Eketjäll, Juliette Janson,

Journal of Biological Chemistry

2012

134

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

Susanna Eketjäll, Juliette Janson, Karin Kaspersson,

Journal of Alzheimer s Disease

2016

128

Design and Synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β-Amyloid Peptides

Britt‐Marie Swahn, Karin Kolmodin, Sofia Karlström,

Journal of Medicinal Chemistry

2012

98

Sulfonimidamides as Sulfonamides Bioisosteres: Rational Evaluation through Synthetic, in Vitro, and in Vivo Studies with γ‐Secretase Inhibitors

Fernando W. Sehgelmeble, Juliette Janson, Colin Ray,

ChemMedChem

2012

86

Page 1